Retinitis Pigmentosa

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

The FDA granted rare pediatric disease designation to VG901 for the treatment of retinitis pigmentosa caused by mutations in the CNGA1 gene, according to a press release from ViGeneron.

The FDA cleared the investigational new drug application for a phase 1/2 study investigating VG801, a treatment for Stargardt disease and other retinal diseases associated with mutations in the ABCA4 gene.

OCU410, a single-dose modifier gene therapy, demonstrated positive preliminary outcomes for the treatment of geographic atrophy in a phase 1/2 clinical trial, according to a press release from Ocugen.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sujay Jadhav, CEO of Verana Health, discusses two of the company’s new data collection modules which launched during the AAO meeting.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sam Barone, MD, of Nanoscope Therapeutics discusses the mutation-agnostic gene therapy MCO-010.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Allen C. Ho, MD, of Wills Eye Hospital shares promising results of a phase 2b/3 trial investigating MCO-010 optogenetic therapy for the treatment of retinitis pigmentosa.

In this Healio Video Perspective from the ASRS meeting, Michael A. Singer, MD, of the University of Texas Health Science Center in San Antonio, discusses topline results for MCO-010 for the treatment of retinitis pigmentosa.

The FDA approved Ocugen’s expanded access program for the treatment of retinitis pigmentosa with OCU400, according to a press release.

A 65-year-old man presented to the retina service for a preoperative cataract surgery evaluation after being followed for years for presumed retinitis pigmentosa.